Efavirenz, lamivudine, and tenofovir and Fosamprenavir interaction

Efavirenz, lamivudine, and tenofovir and Fosamprenavir: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.

Major

Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.

What the FDA labels say

From the Efavirenz, lamivudine, and tenofovir (SYMFI) label · effective 2019-10-15

Major

Lactic Acidosis and Severe Hepatomegaly with Steatosis Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs and other antiretrovirals.

Warnings and precautionsby drug classView label on DailyMed
Major

• SYMFI should not be administered with other antiretroviral medications for the treatment of HIV-1 infection.

Drug interactionsby drug classView label on DailyMed
Major

Not Recommended with Other Antiretroviral Medications SYMFI is a complete regimen for the treatment of HIV-1 infection; therefore, it should not be administered with other antiretroviral medications for treatment of HIV-1 infection.

Drug interactionsby drug classView label on DailyMed

From the Fosamprenavir (Fosamprenavir Calcium) label · effective 2026-06-30

Moderate

Fosamprenavir calcium/ritonavir: ↑ Amprenavir ↓Delavirdine Non-nucleoside reverse transcriptase inhibitor: Efavirenz a Fosamprenavir calcium: ↓ Amprenavir Fosamprenavir calcium/ritonavir: ↓ Amprenavir Appropriate doses of the combinations with respect to safety and efficacy have not been established.

Drug interactionsnames Efavirenz, lamivudine, and tenofovirView label on DailyMed
Moderate

No change in the ritonavir dose is required when efavirenz is administered with Fosamprenavir calcium plus ritonavir twice daily.

Drug interactionsnames Efavirenz, lamivudine, and tenofovirView label on DailyMed
Moderate

Initiation of medications that inhibit or induce CYP3A may increase or decrease concentrations of fosamprenavir calcium/ritonavir, respectively.

Warnings and precautionsby drug classView label on DailyMed
Moderate

Coadministration of fosamprenavir calcium with drugs that induce CYP3A4 may decrease amprenavir (active metabolite) concentrations leading to potential loss of virologic activity.

Drug interactionsby drug classView label on DailyMed
Moderate

Coadministration of fosamprenavir calcium and drugs that induce CYP3A4, such as rifampin, may decrease amprenavir concentrations and reduce its therapeutic effect.

Drug interactionsby drug classView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.